IL-17A inhibition may have dual effects, alleviating inflammation, but also damaging the function of already impaired intestinal epithelial barrier, causing colitis (Ogawa et al., 2004; Schreiber et al., 2019). The gene discussed is IL17A; the disease is colitis.